Gilead Sciences Inc. Aug. 10 announced that the Food and Drug Administration has approved the HIV drug Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate).
The Foster City, Calif.-based company described Complera as a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naive adults. The company said Complera combines three antiretroviral medications in one daily tablet: Gilead’s Truvada, which is a fixed-dose combination of the two nucleoside reverse transcriptase inhibitors, emtricitabine and tenofovir disoproxil fumarate; and Tibotec Pharmaceuticals’ non-nucleoside reverse transcriptase inhibitor, rilpivirine (marketed as Edurant in the United States by Johnson & Johnson unit Janssen Therapeutics).
Gilead said that Truvada and ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.